Compare BH & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | SDGR |
|---|---|---|
| Founded | 1934 | 1990 |
| Country | United States | United States |
| Employees | 2359 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.1M | 925.8M |
| IPO Year | N/A | 2020 |
| Metric | BH | SDGR |
|---|---|---|
| Price | $289.71 | $15.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 60.0K | ★ 1.2M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | N/A | $0.76 |
| Revenue Next Year | N/A | $4.60 |
| P/E Ratio | $597.67 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $234.92 | $10.95 |
| 52 Week High | $483.60 | $27.63 |
| Indicator | BH | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 73.89 |
| Support Level | $266.53 | $11.27 |
| Resistance Level | $321.70 | $19.51 |
| Average True Range (ATR) | 17.34 | 0.71 |
| MACD | 3.60 | 0.22 |
| Stochastic Oscillator | 81.68 | 91.87 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.